7月15日，港股市场生物技术板块表现强势，其中荣昌生物（09995.HK）在盘中大幅上涨5.08%，截至13时02分，该股报67.200港元。成交量达589.438万股，换手率为2.83%，振幅6.57%。
资金流向方面，荣昌生物当日净流入约6605万港元。值得注意的是，南向资金近期持续增持该股。7月14日，南向资金增持荣昌生物123.25万股，连续4日增持。截至当日收盘，港股通共持有荣昌生物10935.24万股，占流通股52.43%。
分析人士认为，荣昌生物股价上涨可能受到多重因素推动。首先，创新药板块整体表现强劲，生物技术行业当日整体涨幅达1.52%。其次，多只医药主题基金最新披露的二季报显示，荣昌生物被纳入部分基金的前十大重仓股，反映出机构投资者对该公司的看好。此外，业内人士持续看好创新药板块，认为中国创新药正处于产业红利释放的前夜，具备硬科技实力、能持续创造临床价值的企业有望穿越周期，这也为荣昌生物等创新药企业提供了利好支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.